Chiusura precedente | 10,03 |
Aperto | 10,08 |
Denaro | 0,00 x N/D |
Lettera | 0,00 x N/D |
Min-Max giorno | 9,62 - 10,12 |
Intervallo di 52 settimane | 0,69 - 10,12 |
Volume | |
Media Volume | 27.079 |
Capitalizzazione | 7,753M |
Beta (5 anni mensile) | 0,79 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -1,58 |
Prossima data utili | 09 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Aqueous Aflibercept Protein Expression Levels in LUNA and OPTIC Trials Aqueous aflibercept protein expression levels from LUNA and OPTIC trials at Week 14 and 12, respectively. - Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range - - Ixo-vec has been well tolerated with a favorable preliminary safety profile - - Initial Phase 2 LUNA efficacy and safety data anticipated in Q4 2023 -
REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Adverum Biotechnologies will present at the following upcoming investor conferences: Cantor Fitzgerald Global Healthcare Conference 2023 on Thursday, September 28, 2023 at 8:00 a.m. ET.Chardan’s 7th Annual Genetics Medicines Conference on Monday, Octo
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that Linda Rubinstein, chief financial officer of Adverum Biotechnologies, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023. The on-demand webcast corporate presentation may be accessed under Event